We report a case of sinus mucormycosis in a patient receiving infliximab for Crohn’s disease (CD). A 41-year-old white female with a history of gastroesophageal reflux disease, well-controlled diabetes, and ileocecal CD developed right-sided facial pain and high fevers, with computed tomography scan confirming sinusitis. She had been receiving both low-dose azathioprine and scheduled infliximab for her CD. A sinus biopsy was procured endoscopically which grew mucormycosis. All immunosuppressive agents were immediately discontinued, and the patient underwent multiple debridement procedures of the right sinuses. Amphotericin B lipid complex and posaconazole were administered to the patient. Repeat laboratory and imaging study demonstrated clearance of the infection approximately 30 days after diagnosis. The patient’s CD did not flair during withdrawal of immunosuppressive medications, and the patient completed 6 months of posaconazole therapy. Clinicians should be aware of the possible development of this potentially catastrophic infection in patients receiving infliximab, especially if such patients have other risks for mucormycosis, such as diabetes.

Keywords:
Mucormycosis, Infliximab, Crohn’s disease
1.
Travis SP, Stange EF, Lémann M, et al: European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006;55(suppl 1):i16–i35.
2.
Hansen RA, Gartlehner G, Powell GE, Sandler RS: Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 2007;5:729–735.
3.
Reddy JG, Loftus EV Jr: Safety of infliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35:837–855.
4.
Alderson JW, Van Dinter TG Jr, Opatowsky MJ, Burton EC: Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn’s disease and chronic hepatitis C: a case study and review of the literature. MedGenMed 2005;7:7.
5.
Spellberg B, Edwards J Jr, Ibrahim A: Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556–569.
6.
Tehmeena W, Hussain W, Zargar HR, Sheikh AR, Iqbal S: Primary cutaneous mucormycosis in an immunocompetent host. Mycopathologia 2007;164:197–199.
7.
Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D’Souza O: Rhino-orbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes. Indian J Ophthalmol 2003;51:231–236.
8.
Brown J: Zygomycosis: an emerging fungal infection. Am J Health Syst Pharm 2005;62:2593–2596.
9.
Chayakulkeeree M, Ghannoum MA, Perfect JR: Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006;25:215–229.
10.
Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL: The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clin Infect Dis 1998;27:1138–1147.
11.
Marty FM, Cosimi LA, Baden LR: Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004;350:950–952.
12.
American Diabetes Association: Standards of medical care in diabetes – 2008. Diabetes Care 2008;31:S12–S54.
13.
Naranjo CA, Busto U, Sellers EM, et al: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
14.
Singh P, Taylor SF, Murali R, Gomes LJ, Kanthan GL, Maloof AJ: Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. Clin Experiment Ophthalmol 2007;35:275–280.
15.
Gadadhar H, Hawkins S, Huffstutter JE, Panda M: Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy. J Clin Rheumatol 2007;13:361–362.
16.
Devlin SM, Hu B, Ippoliti A: Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn’s disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig Dis Sci 2007;52:2078–2081.
17.
Odessey E, Cohn A, Beaman K, Schechter L: Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. Surg Infect 2008;9:91–98.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.